There's nothing swampier than handing over billions of taxpayer dollars to a pharmaceutical company that had already gotten ...

Enveric Biosciences secures a U.S. patent for non-hallucinogenic mescaline derivatives targeting addiction, ADHD and anxiety.

Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of ...

Some e-cigarette companies targeted by U.S. authorities have altered their business model or changed their corporate ...

TAMPA, FL / ACCESS Newswire / February 25, 2025 / CTT Pharmaceutical Holdings, Inc. (OTC PINK:CTTH) has received notification of an intention to grant from the European Patent Office(EPO) for ...

In recent years, the rapid advancement of artificial intelligence (AI) and machine learning (ML) technologies has sparked a ...

The narrative surrounding Nigeria’s recent drug market raid has been dangerously skewed. What many perceive as heavy-handed overreach ...

Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is complete ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...

A significant number of Americans experience chronic inflammatory skin conditions with no pinpointed cause and often no ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

If these laws proceed, they will restrict access to essential remedies and severely limit consumer choice,' says Canadian ...